Articles tagged with Blood Cancer
A clinical trial found that linvoseltamab, a bispecific antibody, eliminated 90% of tumor cells in patients with residual disease. The treatment allows patients to bypass high-dose chemotherapy and bone marrow transplants, potentially improving long-term outcomes.
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.
Researchers from Penn Medicine will present data on latest advances in blood cancer and classical hematology research at the 67th American Society of Hematology Annual Meeting. The presentation includes updates on preclinical, clinical, and population-based research, as well as a multicenter Phase II study and a randomized phase III tr...
A new study from Cincinnati Children's reveals how Fanconi anemia disrupts energy pathways and affects glucose metabolism, paving the way for targeted dietary interventions to improve health and reduce cancer risk. The research uses isotope tracing metabolomics to track nutrient metabolism in people with FA.
A new protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications, boosting survival rates while preserving anti-cancer immunity. The protocol, led by Robert Levy, uses TL1A-Ig fusion protein and low-dose IL-2 to stimulate specific receptors on Tregs, promoting a safer environment for stem cell transplants.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
A recent study found that young donors (18-35 years old) with minor HLA differences can provide better survival rates and outcomes compared to older sibling donors. Additionally, gender and CMV status also play a role in donor selection.
Researchers have developed a system called CytoDiffusion that uses generative AI to study the shape and structure of blood cells. The system can accurately identify normal blood cell appearances and spot unusual or rare cells that may indicate disease, outperforming existing systems in tests.
Researchers have made significant advancements in diagnosing acute myeloid leukemia (AML), a common and aggressive form of blood cancer. Genetic testing can now predict relapse after stem cell transplant and detect hidden gene fusions that were previously undetectable.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
Researchers identified a new subtype of T-cells that do not respond to current treatments and could impact clinical care. A genetic marker, ZBTB16, was found to be switched on in these cells, which can be used to identify them.
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
Researchers at MD Anderson Cancer Center identified distinct cellular microenvironments in diffuse large B-cell lymphoma tumors, providing a framework to develop therapies that engage the patient's immune system. Additionally, a study found widespread misbeliefs about the cancer risks of alcohol among Americans, highlighting the need f...
Researchers developed a computational platform to design synthetic protein receptors that can detect tumor signals and boost T cell activity. The new receptors, called T-SenSERs, showed improved tumor control and longer survival in mouse models of lung cancer and multiple myeloma.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Recent studies from Sylvester have uncovered links between breast cancer, Superfund sites and social adversity. Researchers are also exploring the use of artificial intelligence (AI) in interpreting mammograms more accurately.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
The Josep Carreras Institute is pioneering Spatial Transcriptomics to understand tumor structure at the cellular level. The institute's guidance on this methodology offers practical solutions for improving reproducibility and clinical application.
Scientists at Institut Pasteur and Inserm developed a triple-therapy approach to treat blood cancers like lymphomas and leukemias. They induced necroptosis in malignant B cells, which activates the immune system to eliminate tumor cells.
The ASAP study found that transplantation as soon as possible does not provide a survival advantage over remission induction, but reduces hospital stays and chemotherapy exposure. Age and AML genetics are the most important risk factors influencing survival.
A study of 9/11 first responders found mutations in blood-forming cells may explain increased leukemia risk, suggesting a targeted intervention against environmental toxins. The research also identified IL1RAP as a protein culprit, which could be used to prevent or treat blood cancers in individuals exposed to similar disasters.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.
Duke University researchers discovered that inhibiting an enzyme involved in iron regulation makes cancer cells vulnerable to cell death. By targeting STK17B kinase, they reactivated ferroptosis and increased the effectiveness of conventional therapies against multiple myeloma.
A study published in The New England Journal of Medicine found that nearly 4 million children and adolescents were at higher risk of developing blood cancers due to radiation exposure from medical imaging. The researchers estimated that up to 10% of pediatric blood and bone marrow cancers may be attributable to radiation exposure.
The AACR Cancer Progress Report highlights the impact of federal investments on cancer research, with FDA approval of 20 new cancer drugs and improved survival rates. However, challenges such as early-onset cancers and instability at NIH threaten ongoing progress.
A consortium led by the University of Southampton aims to advance cutting-edge treatments for lung cancer, blood cancers, and chronic inflammation. The ON-TRACT project will train researchers in academic, industrial, and clinical settings to develop safer and more effective treatments.
Oral mucositis increases infection risks in stem cell transplant patients by nearly four times, according to new research. A superior AI tool has been introduced to accurately predict these risks, enabling targeted oral care before transplants and reducing complications.
A recent study sequenced human cancers and found little evidence of microbial DNA sequences, contradicting earlier claims. However, microbes linked to human cancer were detected, including HPV, Helicobacter pylori, and Fusobacterium nucleatum.
A new study assesses ChatGPT 3.5's performance on hematology-oncology tasks, revealing its strengths and limitations in providing accurate information for patients. The study highlights the importance of physician oversight when using AI-generated medical information.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Researchers at WashU Medicine found that clonal hematopoiesis, a condition caused by mutated blood stem cells, is more common among individuals with inherited mutations that increase cancer risk. Those with inherited mutations had a higher risk of developing blood cancer if their stem cell clones acquired additional harmful mutations.
A new study reveals that DNA damage in multiple myeloma initiates 2-4 decades before diagnosis, with key genomic events including IGH translocation and chr 1q gain. These findings may lead to new precision medicine treatment strategies for patients.
A young investigator has received prestigious grants to continue research on using RAS inhibitors to treat blood cancers. The studies aim to understand the role of RAS mutations in acute myeloid leukemia and explore potential combination therapies.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
The DKMS John Hansen Research Grant is supporting innovative research projects in blood cancer therapy, aiming to improve treatment outcomes. The grant, worth almost €1 million, will support young scientists with a focus on transplant immunology and novel diagnostic and therapeutic strategies.
The Pew Charitable Trusts has announced the 2025 class of the Pew-Stewart Scholars Program for Cancer Research, supporting five early-career scientists in innovative research projects. The recipients will explore pressing topics such as complex cancer mechanisms and new drug targets.
The study found that only 16% of newly diagnosed patients with MDS on Medicare received HMAs during the period analyzed, with women and non-white patients being less likely to start treatment. The analysis suggests that making changes with existing therapies and administration can have a huge impact on improving outcomes in high-risk MDS.
Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.
A new study has found that TAF1 operates as a key molecular switch in adult hematopoietic stem cell maintenance and lineage commitment. This discovery challenges prevailing models of gene regulation and has the potential to lead to new therapeutic strategies targeting the molecule, which could improve blood production and transplantation.
A new breath test has been developed to detect blood cancers, showing promise for early diagnosis and treatment monitoring. The test uses exhaled breath analysis to identify molecules produced by cancer cells, potentially providing a quick and affordable diagnostic tool for areas with limited access to specialist equipment.
New research from Sylvester Comprehensive Cancer Center shows that partial match transplants can achieve good outcomes with cyclophosphamide treatment. Additionally, lifestyle medicine is playing a pivotal role in improving patient outcomes for cancer survivors.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
Researchers developed a novel immunotherapy that disrupts the IL-33/IL1RL1 signaling loop to boost immune function and improve survival in leukemia patients. The treatment targeted leukemia stem cells, reducing relapse rates and improving survival without major side effects.
The Damon Runyon Cancer Research Foundation has awarded $4.2 million to five new Clinical Investigators conducting patient-oriented cancer research. The awards will support the development of new treatments for cancer patients, with a focus on enhancing efficacy and safety.
The revised guidelines incorporate the latest clinical advances in graft-versus-host disease prophylaxis, expanded donor options and search strategies. The updated guidelines aim to enhance transplant outcomes for patients with blood cancers and disorders.
A new bioinformatic tool called Cell Marker Accordion has been developed to help researchers understand single-cell analysis results. The tool reveals the presence of altered cells that may be linked to diseases such as blood cancers or solid tumours, and can identify unique genes involved in these alterations.
A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.
Researchers created a powerful cell culture model using induced pluripotent stem cells from a patient with MDS, confirming that the CEBPA mutation drives disease progression. The model could lead to new ways to treat and diagnose MDS and avoid more serious conditions.
Scientists have developed a miniature device that mimics human bone marrow and immune environment, enabling predictive testing of cancer immunotherapy success in patients. The device recreates three regions of bone marrow where leukemia develops and retains the complex immune environment of the tissue.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
A recent study found that blood cancer patients achieve good outcomes with a partial match drawn from the national public registry of donors when treated with cyclophosphamide. Survival rates at one year were comparable to those seen in other studies with fully matched donors.
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
A phase 1 clinical study will assess the safety and efficacy of JBZ-001 in patients with AML. The study is supported by a $3.4 million grant from the National Cancer Institute and aims to improve efficiency for the therapeutic pipeline.
Researchers developed a tool to monitor treatment response in patients with solid tumours using circulating tumour DNA analysis, anticipating clinical relapses up to 68 months before symptoms become apparent. The technology is minimally invasive and can be tailored to each tumour type, reducing unnecessary treatments and costs.